Anti-PF4/polyanion antibodies in COVID-19 patients are associated with disease severity and pulmonary pathology

References

• Bosmuller H, Matter M, Fend F, Tzankov A. The pulmonary pathology of COVID-19. Virchows Arch 2021;478:137–150. doi:10.1007/s00428-021-03053-1.
   PubMed Web of Science ®Google Scholar
• Lowenstein CJ, Solomon SD. Severe COVID-19 is a microvascular disease. Circulation 2020;142:1609–1611. doi:10.1161/CIRCULATIONAHA.120.050354.
   PubMed Web of Science ®Google Scholar
• O’Donnell JS, Peyvandi F, Martin-Loeches I. Pulmonary immuno-thrombosis in COVID-19 ARDS pathogenesis. Intensive Care Med 2021;47:899–902. doi:10.1007/s00134-021-06419-w.
   PubMed Web of Science ®Google Scholar
• Daviet F, Guervilly C, Baldesi O, Bernard-Guervilly F, Pilarczyk E, Genin A, Lefebvre L, Forel JM, Papazian L, Camoin-Jau L, et al. Heparin-induced thrombocytopenia in severe COVID-19. Circulation 2020;142:1875–1877. doi:10.1161/CIRCULATIONAHA.120.049015.
   PubMed Web of Science ®Google Scholar
• Uaprasert N, Tangcheewinsirikul N, Rojnuckarin P, Patell R, Zwicker JI, Chiasakul T. Heparin-induced thrombocytopenia in patients with Coronavirus disease 2019: systematic review and meta-analysis. Blood Adv 2021;5:4521–4534. doi:10.1182/bloodadvances.2021005314.
   PubMed Web of Science ®Google Scholar
• Dragonetti D, Guarini G, Pizzuti M. Detection of anti-heparin-PF4 complex antibodies in COVID-19 patients on heparin therapy. Blood Transfus 2020;18:328. doi:10.2450/2020.0164-20.
   PubMed Web of Science ®Google Scholar
• Nazy I, Jevtic SD, Moore JC, Huynh A, Smith JW, Kelton JG, Arnold DM. Platelet-activating immune complexes identified in critically ill COVID-19 patients suspected of heparin-induced thrombocytopenia. J Thromb Haemost 2021;19:1342–1347. doi:10.1111/jth.15283.
   PubMed Web of Science ®Google Scholar
• Brodard J, Kremer Hovinga JA, Fontana P, Studt JD, Gruel Y, Greinacher A. COVID-19 patients often show high-titer non-platelet-activating anti-PF4/heparin IgG antibodies. J Thromb Haemost 2021;19:1294–1298. doi:10.1111/jth.15262.
   PubMed Web of Science ®Google Scholar
• Pascreau T, Ballester MC, Van Dreden P, Zia-Chahabi S, Zuber B, Choucair J, Bironien R, Farfour E, Vasse M. The high frequency of anti-PF4/heparin antibodies in patients with COVID-19 is neither related to heparin treatment or to an increased incidence of thrombosis. Clin Chem Lab Med 2021;59:e405–e408. doi:10.1515/cclm-2021-0623.
   PubMed Web of Science ®Google Scholar
• Barratt-Due A, Olsen IC, Nezvalova-Henriksen K, Kåsine T, Lund-Johansen F, Hoel H, Holten AR, Tveita A, Mathiessen A, Haugli M, et al. Evaluation of the effects of remdesivir and hydroxychloroquine on viral clearance in COVID-19: a randomized trial. Ann Intern Med 2021;174:1261–1269. doi:10.7326/M21-0653.
   PubMed Web of Science ®Google Scholar
• Sørvoll IH, Horvei KD, Ernstsen SL, Lægreid IJ, Lund S, Grønli RH, Olsen MK, Jacobsen HK, Eriksson A, Halstensen AM, et al. An observational study to identify the prevalence of thrombocytopenia and anti-PF4/polyanion antibodies in Norwegian health care workers after COVID-19 vaccination. J Thromb Haemost 2021;19:1813–1818. doi:10.1111/jth.15352.
   PubMed Web of Science ®Google Scholar
• Lerum TV, Maltzahn NN, Aukrust P, Trøseid M, Henriksen KN, Kåsine T, Dyrhol-Riise A-M, Stiksrud B, Haugli M, Blomberg B, et al. Persistent pulmonary pathology after COVID-19 is associated with high viral load, weak antibody response, and high levels of matrix metalloproteinase-9. Sci Rep 2021 Dec 1;11(1):23205. doi:10.1038/s41598-021-02547-x.
   PubMed Web of Science ®Google Scholar
• Hansell DM, Bankier AA, MacMahon H, McLoud TC, Müller NL, Remy J. Fleischner society: glossary of terms for thoracic imaging. Radiology 2008 Mar;246(3):697–722. doi:10.1148/radiol.2462070712.
   PubMed Web of Science ®Google Scholar
• Lerum TV, Aaløkken TM, Brønstad E, Aarli B, Ikdahl E, Lund KMA, Durheim MT, Rodriguez JR, Meltzer C, Tonby K, et al. Dyspnoea, lung function and CT findings 3 months after hospital admission for COVID-19. Eur Respir J 2021 Apr 29;57(4):2003448. doi:10.1183/13993003.03448-2020.
   PubMed Web of Science ®Google Scholar
• Padmanabhan A, Jones CG, Curtis BR, Bougie DW, Sullivan MJ, Peswani N, McFarland JG, Eastwood D, Wang D, Aster RH, et al. A novel PF4-dependent platelet activation assay identifies patients likely to have heparin-induced thrombocytopenia/thrombosis. Chest 2016;150:506–515. doi:10.1016/j.chest.2016.02.641.
   PubMed Web of Science ®Google Scholar
• Schultz NH, Sorvoll IH, Michelsen AE, Munthe LA, Lund-Johansen F, Ahlen MT, Wiedmann M, Aamodt A-H, Skattør TH, Tjønnfjord GE, et al. Thrombosis and thrombocytopenia after ChAdOx1 nCoV-19 vaccination. N Engl J Med 2021;384:2124–2130. doi:10.1056/NEJMoa2104882.
   PubMed Web of Science ®Google Scholar
• Greinacher A, Thiele T, Warkentin TE, Weisser K, Kyrle PA, Eichinger S. Thrombotic Thrombocytopenia after ChAdOx1 nCov-19 vaccination. N Engl J Med 2021;384:2092–2101. doi:10.1056/NEJMoa2104840.
   PubMed Web of Science ®Google Scholar
• Scully M, Singh D, Lown R, Poles A, Solomon T, Levi M, Goldblatt D, Kotoucek P, Thomas W, Lester W, et al. Pathologic antibodies to platelet factor 4 after ChAdOx1 nCoV-19 vaccination. N Engl J Med 2021;384:2202–2211. doi:10.1056/NEJMoa2105385.
   PubMed Web of Science ®Google Scholar
• Delrue M, Siguret V, Neuwirth M, Brumpt C, Voicu S, Burlacu R, Sène D, Chousterman BG, Mohamedi N, Lecompte T, et al. Contrast between prevalence of HIT antibodies and confirmed HIT in hospitalized COVID-19 patients: a prospective study with clinical implications. Thromb Haemost 2021;121:971–975. doi:10.1055/a-1333-4688.
   PubMed Web of Science ®Google Scholar
• Pardo A, Gibson K, Cisneros J, Richards TJ, Yang Y, Becerril C, Yousem S, Herrera I, Ruiz V, Selman M, et al. Up-regulation and profibrotic role of osteopontin in human idiopathic pulmonary fibrosis. PLoS Med 2005;2:e251. doi:10.1371/journal.pmed.0020251.
   PubMed Web of Science ®Google Scholar
• Kolmel S, Hobohm L, Kaberich A, Krieg VJ, Bochenek ML, Wenzel P, Wiedenroth CB, Liebetrau C, Hasenfuß G, Mayer E, et al. Potential involvement of osteopontin in inflammatory and fibrotic processes in pulmonary embolism and chronic thromboembolic pulmonary hypertension. Thromb Haemost 2019;119:1332–1346. doi:10.1055/s-0039-1692174.
   PubMed Web of Science ®Google Scholar